205 related articles for article (PubMed ID: 20470305)
1. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Ferrari P; Mallon D; Trinder D; Olynyk JK
Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
[TBL] [Abstract][Full Text] [Related]
2. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004.
Fishbane S; Pollack S; Feldman HI; Joffe MM
Clin J Am Soc Nephrol; 2009 Jan; 4(1):57-61. PubMed ID: 18987297
[TBL] [Abstract][Full Text] [Related]
3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
6. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin for clinicians.
Young B; Zaritsky J
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
9. Assessing iron status: beyond serum ferritin and transferrin saturation.
Wish JB
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
12. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
13. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
14. Heart and iron deficiency anaemia in rats with renal insufficiency: the role of hepcidin.
Toblli JE; Cao G; Rivas C; Kulaksiz H
Nephrology (Carlton); 2008 Oct; 13(7):636-45. PubMed ID: 18808386
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin and iron deficiency in pre-kidney transplant patients.
Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
17. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
18. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
Gasche C; Waldhoer T; Feichtenschlager T; Male C; Mayer A; Mittermaier C; Petritsch W;
Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
